Vaccines Medical Affairs, Pfizer Korea, Korea.
Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
Expert Rev Vaccines. 2023 Jan-Dec;22(1):327-340. doi: 10.1080/14760584.2023.2189459.
Respiratory syncytial virus (RSV) infection is one of the most common causes of acute respiratory tract infections in young children and the elderly. Infants and young children aged <2 years and the elderly are at particular risk of severe infections requiring hospitalization.
This narrative review summarizes the epidemiology of RSV infection in Korea, with a particular focus on infants and the elderly, where possible, and highlights the need for effective vaccinations against RSV. Relevant papers were identified from a search of PubMed up to December 2021.
RSV infection is associated with a significant burden of illness in infants and the elderly worldwide and accounts for a substantial number of hospital admissions due to severe lower respiratory tract infections in both of these age groups in Korea. Vaccination has the potential to reduce the burden of acute RSV-associated disease and long-term consequences such as asthma. Increased understanding of the immune response to RSV, including mucosal immunity, and the innate and adaptive immune responses is needed. Technological advances in vaccine platforms could provide better approaches for achieving a safe and effective vaccine-induced immune response.
呼吸道合胞病毒（RSV）感染是导致婴幼儿和老年人急性呼吸道感染的最常见原因之一。<2 岁的婴儿和幼儿以及老年人特别容易发生需要住院治疗的严重感染。
本综述性叙述总结了韩国 RSV 感染的流行病学情况，特别关注婴儿和老年人，并强调了针对 RSV 进行有效疫苗接种的必要性。相关论文通过对截至 2021 年 12 月 PubMed 的检索而确定。
RSV 感染在全球范围内给婴幼儿和老年人带来了巨大的疾病负担，并且在韩国，这两个年龄段都有大量因严重下呼吸道感染而住院的病例。疫苗接种有可能减轻急性 RSV 相关疾病和哮喘等长期后果的负担。需要进一步了解 RSV 的免疫反应，包括黏膜免疫以及先天和适应性免疫反应。疫苗平台技术的进步可以为实现安全有效的疫苗诱导免疫反应提供更好的方法。
